Trial Profile
Impact of Lenvatinib or Vandetanib treatment on fatigue and adrenal function in patients with advanced Radioiodine refractory differentiated thyroid cancer and Medullary thyroid cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Pharmacodynamics
- 29 Nov 2018 New trial record
- 31 Oct 2018 Results published in the Journal of Clinical Endocrinology and Metabolism